Skip to main content
 

FierceBiotech: Novartis steps in to help bankroll CRISPR-Cas9 pioneer Caribou

April 2, 2015

Pharma heavyweight Novartis has stepped in to help bankroll Berkeley, CA-based Caribou Biosciences, one of the upstart leaders in the race to develop the cutting-edge CRISPR-Cas9 gene editing technology. 

Nature Biotechnology: Nature Biotechnology's academic spinouts of 2014

March 6, 2015

Ventures focusing on drug testing or therapies against rare disease, cancer, gastrointestinal disease, fibrosis and pain are among those selected by the editors in 2014's crop of startups.

Genetic Engineering News: Novartis Launches CRISPR Collaborations with Intellia, Caribou

January 7, 2015

Novartis said today it is launching collaborations with a pair of partners that will enable it to use CRISPR genome editing technology to discover and develop new medicines. The value of both collaborations was undisclosed.

Reuters: Novartis taps into gene editing for next generation drugs

January 7, 2015

Novartis is diving deeper into the world of gene-based medicine by signing deals with two U.S. biotech companies, giving it access to a powerful new genome editing technology.

PharmaTimes: Novartis in genome editing pacts with Intellia, Caribou

January 7, 2015

Novartis is buying into CRISPR gene editing technology via two separate deals with Intellia Therapeutics and Caribou Biosciences.

 

Pages